secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-11-26T23:59:59+00:00
Accession:  0001193125-25-300538
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics retention program grants cash and RSUs to CEO, CFO, CMO tied to TSC-101 milestone
--------------------------------------------------------------------------------

- Board approved retention program for CEO Gavin MacBeath, CFO Jason Amello, and CMO Chrystal Louis.
- Cash awards: $399K (CEO), $170K (CFO), $250K (CMO); 50% paid upon TSC-101 pivotal trial milestone, 50% on first anniversary.
- Equity awards: 1M RSUs (CEO), 270K RSUs (CFO), 650K RSUs (CMO) granted upon milestone; vest 25% at year 2, 75% at trial completion or year 4.
- Awards subject to continued employment and terms of 2021 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525300538/0001193125-25-300538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525300538/d41366d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-300538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer